Two deaths halt Re­gen­eron’s prostate can­cer bis­pe­cif­ic an­ti­body tri­al as it looks at tweak­ing com­bo plans

Re­gen­eron is ex­plor­ing next steps with its PS­MA/CD28 bis­pe­cif­ic an­ti­body de­vel­op­ment in prostate can­cer af­ter two pa­tient deaths in a com­bo tri­al with Lib­tayo. The set­back comes a year af­ter the com­pa­ny drew buzz for the com­bo with its po­ten­tial to add depth to the im­munother­a­py ar­ma­men­tar­i­um.

On Thurs­day, Re­gen­eron re­vealed two im­mune-me­di­at­ed deaths, one as re­cent­ly as Ju­ly, in pa­tients re­ceiv­ing REGN5678 plus its own PD-1 check­point in­hibitor Lib­tayo. “Due to the emerg­ing safe­ty pro­file,” in­clud­ing the pa­tient deaths, the com­pa­ny has dis­con­tin­ued pa­tient en­roll­ment in the tri­al, ac­cord­ing to an SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER